Project Grant R41TR005122
Award Date
4/15/24
Completion Date
4/14/25
Dollars Obligated
$350K
Federal Agency
National Center for Advancing Translational Sciences
Awardee
Codomax Inc. (EV4LS8M87WU7)
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This $350,000 Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under the 93.350 CFDA program, supports the development of the Codomax EPI-MAX platform. This integrated omics and computational technology leverages cellular stress responses to enhance the production of difficult-to-express therapeutic proteins, with a focus on improving secretion and preventing aggregation in the Pichia pastoris expression system. The key products or services to be...
The National Center for Advancing Translational Sciences (NCATS), under the CFDA Program 93.350, awarded a $338,997 Project Grant to Mabswitch Inc. effective January 1, 2024 to December 31, 2024. The project aims to develop "LENTISAFE LIGANDS: MILD-ELUTION IMMUNOAFFINITY LIGANDS FOR ENRICHMENT AND PURIFICATION OF LENTIVIRAL VECTORS." The goal is to create switchable affinity ligands that can be used to selectively isolate and enrich functional lentiviral vectors from production...
The National Center for Advancing Translational Sciences (NCATS) awarded a $275,000 Project Grant (CFDA 93.350) to Nectagen Inc. to develop bioprocess-compatible, second-generation nanoclamp affinity resins for the efficient purification of plasma-based therapeutic proteins. The goal is to identify panels of nanoclamps to 5 industrially relevant plasma-based therapeutics, select lead candidates, and optimize the resins for maximum recovery and purity from plasma samples. This project aims to...
The National Science Foundation (NSF) awarded a $550,000 Project Grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Clemson University. The grant, awarded on August 15, 2024, with a completion date of January 31, 2026, funds the development of a novel, automated microwave system for comprehensive single-cell measurement and characterization of high-performing, stable Chinese Hamster Ovary (CHO) cells. The key products and services to be delivered through this...
This $842,151 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the development of an improved, low-endotoxin E. coli strain for the production of biological products such as recombinant proteins and plasmid DNA. The awardee, Scarab Genomics LLC, a biotechnology company in Madison, Wisconsin, will use genetic engineering techniques to substantially lower the level of contaminating endotoxin...
This $650,000 Project Grant awarded by the National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, supports research and development for a next generation probiotics-based platform technology to enable oral delivery of peptide and protein therapeutics. Specifically, the project aims to (1) develop an antibiotic-resistance-free expression system for stable, high-level production of therapeutic peptides in Lactobacillus probiotic strains, (2) create inducible...
The National Center for Advancing Translational Sciences (NCATS), through its CFDA 93.350 Federal Grant Program, awarded a $294,541 Project Grant to Cellular Vehicles Inc. on June 1, 2024. The purpose of this award is to develop an automated system for producing and delivering cell-laden hydrogel therapies. The project aims to create a novel, standardized process for formulating, encapsulating, and directly injecting cell-laden hydrogels into diseased tissues. This is intended to improve the...
This Project Grant award of $350,000 from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training (CFDA 93.859) program, supports Cisterna Biologics, Inc. in developing a novel production and purification process for ultra-pure mRNA. The project aims to address critical challenges in mRNA purification for therapeutic applications by leveraging psychrophilic (cold-adapted) RNA polymerases and Cisterna's proprietary purification technology to...
This Project Grant award of $1,000,000 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports the development of advanced antibody discovery workflows by Partillion Bioscience Corp, a for-profit biotechnology company based in Los Angeles, California. The grant aims to significantly enhance Partillion's proprietary "nanovial" technology, which enables ultra high-throughput screening and functional assessment of...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $205,926 to Abbratech Inc., a small disadvantaged biotechnology business located in Branford, CT. The overarching goal of this "Fast Track" research project is to develop a comprehensive platform for identifying and validating recombinant antibodies that target protein isoform splice-junction sites. This addresses key...